Klebsiella Infections Pipeline Insight
DelveInsight’s, “Klebsiella Infections - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Klebsiella Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Klebsiella Infections Understanding
Klebsiella Infections: Overview
Klebsiella is a type of bacteria commonly found in nature. In humans, the bacteria are often present in parts of the digestive tract where they do not generally cause problems. In the United States, Klebsiella pneumoniae and Klebsiella oxytoca are the two strains responsible for most human illnesses. Many Klebsiella Infections are acquired in the hospital setting or in long-term care facilities. In fact, Klebsiellae account for up to 8% of all hospital-acquired infections. People with a compromised immune system and/or people who have an implanted medical device (such as a urinary catheter or airway tube) are more at risk for Klebsiella Infections. Extensive use of antibiotics has resulted in the development of antibiotic-resistant strains of Klebsiella. These infections can be more aggressive and difficult to treat
"Klebsiella Infections - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Klebsiella Infections pipeline landscape is provided which includes the disease overview and Klebsiella Infections treatment guidelines. The assessment part of the report embraces, in depth Klebsiella Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Klebsiella Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Klebsiella Infections R&D. The therapies under development are focused on novel approaches to treat/improve Klebsiella Infections.
Klebsiella Infections Emerging Drugs Chapters
This segment of the Klebsiella Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Klebsiella Infections Emerging Drugs
BX003 targets bacterial strains of Klebsiella pneumoniae present in the gut of IBD and PSC patients. In two separate animal studies, different Klebsiella pneumoniae strains were shown to increase disease severity: colitis in IBD models and elevated liver enzymes and fibrosis in PSC models. The suggested underlying mechanism is induction of pro-inflammatory responses characteristic of these diseases, suggesting that these strains may have a role in the onset and aggravation of these diseases (see publication in Science and in Nature Microbiology). These strains were also shown to cause gut permeability or a “leaky gut” that may lead to inflammation in gut in IBD patients and microbial infection of bile ducts, resulting in inflammation and fibrosis within the liver of PSC patients. BX003 is characterized by a broad bacterial host range targeting Klebsiella pneumoniae strains present in the gut of both IBD and PSC patients. A Phase 1b/2a study aimed at evaluating the efficacy of BX003 in reduction of bacterial target with expected results by the end of H2 2022.
Kleb4V: LimmaTech Biologics
LimmaTech Biologics is developing Klebsiella pneumoniae tetravalent bioconjugate vaccine. LimmaTech Biologics uses a proprietary in vivo enzyme-based production method that alleviates the issues associated with the chemical conjugation process. At the core of this approach is a bacterial enzyme capable of forming precise linkages between glycan and protein moieties. The versatility of this platform combined with our extensive glycoengineering experience enables the development of innovative vaccines for multiple pathogens that has not been possible previously. Kleb4V is currently in Phase I/II stage of development.
Further product details are provided in the report……..
Klebsiella Infections: Therapeutic Assessment
This segment of the report provides insights about the different Klebsiella Infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Klebsiella Infections
There are approx. 15+ key companies which are developing the therapies for Klebsiella Infections. The companies which have their Klebsiella Infections drug candidates in the most advanced stage, i.e. phase I/II include, LimmaTech Biologics.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Klebsiella Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Klebsiella Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Klebsiella Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Klebsiella Infections drugs.
Klebsiella Infections Report Insights
- Klebsiella Infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Klebsiella Infections Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Klebsiella Infections drugs?
- How many Klebsiella Infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Klebsiella Infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Klebsiella Infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Klebsiella Infections and their status?
- What are the key designations that have been granted to the emerging drugs?